BioPharma Resources

Drug Trial Radar · NCT06324006

A Phase 1 Trial of LIB-01 in Healthy Participants.

A Phase 1, Randomized, Double-blind, Parallel and Placebo-controlled Single and Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of LIB-01 in Healthy Participants.

Last checked: Nov 19, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Aug 25, 2023

Primary completion

Apr 23, 2024

Study completion May 29, 2024

Sponsor

Lead sponsor
Dicot ABIndustry
Sponsor type
Industry
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants. The main questions it aims to answer are: * How safe and tolerable is LIB-01 when given once or repeatedly at different dose levels. * What are the pharmacokinetic characteristics of LIB-01 Participants will receive LIB-01 and be followed up for safety and pharmacokinetics by: * Adverse events * ECG * Blood sampling for laboratory parameters and pharmacokinetic analysis

Conditions

  • Erectile Dysfunction

Interventions

  • LIB-01Drug

    LIB-01 oral suspension

  • PlaceboOther

    Placebo oral suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
  2. To evaluate changes in vital signs in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
  3. To evaluate changes in ECG in healthy male participants, following a single oral dose of LIB-01.Time frame: 14 days
  4. To evaluate the incidence of treatment-emergent adverse events as assessed by CTCAE in healthy male participants, following multiple oral dosing of LIB-01.Time frame: 28 days
  5. To evaluate changes in vital signs in healthy male participants, following a multiple oral dosing of LIB-01.Time frame: 28 days
  6. To evaluate changes in ECG in healthy male participants, following multiple oral dosing of LIB-01.Time frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Consultants

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.